Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study

NCT03503799 is registered in ClinicalTrials.gov with North Eastern German Society of Gynaecological Oncology as lead sponsor.

NCT NCT03503799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03503799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Phase
Observational
Overall status
Active, not recruiting
Start date
July 17, 2018
Completion date
October 1, 2032
Enrollment
1,191 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive tumor, human epidermal growth factor receptor 2 negative tumor, primary invasive breast cancer